MedTrace Logo

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

NCT02425111 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2018-09-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

Conditions

Interventions

DRUG

Vedolizumab

Vedolizumab intravenous injection

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-30
Primary Completion
2017-06-02
Completion
2018-02-21

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Hungary
  • Italy
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425111 on ClinicalTrials.gov